C12Y 406/01002
Guanylate cyclase
Official title: Guanylate cyclase (4.6.1.2)
C12Y406/01002 (Guanylate cyclase) appears on 31 US grants and 65 published applications in this corpus.
Search patents in C12Y- Granted patents
- 31
- Published applications
- 65
- Assignees
- 39
- Inventors
- 118
- Latest grant
- 17 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 3 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 3 |
| 2014 | 3 | 2 |
| 2015 | 1 | 3 |
| 2016 | 2 | 4 |
| 2017 | 4 | 6 |
| 2018 | 5 | 3 |
| 2019 | 2 | 3 |
| 2020 | 2 | 6 |
| 2021 | 3 | 5 |
| 2022 | 1 | 3 |
| 2023 | 2 | 3 |
| 2024 | 5 | 6 |
| 2025 | 0 | 6 |
| 2026 | 0 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Guide RNA that targets a mutant human guanylate cyclase 2A allele17 Dec 2024US 12,168,062 B2EmendoBio Inc.
- Ultra-pure agonists of guanylate cyclase C, method of making and using same19 Nov 2024US 12,146,003 B2Bausch Health Ireland Limited
- Anti-GCC antibody and CAR thereof for treating digestive system cancer23 Jul 2024US 12,043,654 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Minimally-invasive measurement of esophageal inflammation7 May 2024US 11,974,730 B2The Board of Trustees of the University of Illinois
- Nanobody target GCC and uses in chimeric antigen receptor cell therapy30 Apr 2024US 11,970,548 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Gucy2c t cell-antigen couplers and uses thereof4 Jun 2026US 2026/0151483 A1Triumvira Immunologics USA, Inc.
- Humanized gucy2c t cell-antigen couplers and uses thereof21 May 2026US 2026/0137784 A1Triumvira Immunologics USA, Inc.
- Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy26 Feb 2026US 2026/0055209 A1Innovative Cellular Therapeutics Holdings, Ltd.
- Antigen-binding molecule specifically binding to gucy2c and cd3 and pharmaceutical use thereof29 Jan 2026US 2026/0028421 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Anti-gucy2c vaccines and vaccination9 Oct 2025US 2025/0312429 A1Thomas Jefferson University
Most cited
By later US patents
- Minimally-invasive measurement of esophageal inflammation34US 8,637,239 B2The Board of Trustees of the University of Illinois · 2014
- Genetic products differentially expressed in tumors and the use thereof18US 9,044,382 B2Ganymed Pharmaceuticals AG · 2015
- Ultra-pure agonists of guanylate cyclase C, method of making and using same7US 10,011,637 B2Synergy Pharmaceuticals, Inc. · 2018
- Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides6US 10,301,629 B2Portage Pharmaceuticals Ltd. · 2019
- Antibody to genetic products differentially expressed in tumors and the use thereof6US 9,775,785 B2Ganymed Pharmaceuticals AG · 2017